NFDI4DS | UHH-SEMS - Publication Details

Linus Backert

ORCID: 0000-0002-1694-1396

Publications

Citations

Views

---

Saved

---

About

Contact & Profiles

A5017982239

Research Areas

CAR-T cell therapy research
Cancer Research and Treatments
Biomedical Ethics and Regulation
Immunotherapy and Immune Responses
Virus-based gene therapy research
Immune Cell Function and Interaction
vaccines and immunoinformatics approaches
Monoclonal and Polyclonal Antibodies Research
Safe Handling of Antineoplastic Drugs
Cancer Genomics and Diagnostics
Cancer Immunotherapy and Biomarkers
Peptidase Inhibition and Analysis

Immatics Biotechnologies (Germany)
2021-2024

University of Tübingen
2016

First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors

OPENALEX - Publications

Martin Wermke Tobias A.W. Holderried Jason J. Luke Van K. Morris Winfried Alsdorf and 27 more

Rationale of the trial Although use engineered T cells in cancer immunotherapy has greatly advanced treatment hematological malignancies, reaching meaningful clinical responses solid tumors is still challenging. We investigated safety and tolerability IMA202 a first-in-human, dose escalation basket human leucocyte antigen A*02:01 positive patients with melanoma-associated A1 (MAGEA1)-positive tumors. Trial design The 2+2 was an algorithmic based on maximally acceptable dose-limiting toxicity...

10.1136/jitc-2023-008668 article EN cc-by-nc Journal for ImmunoTherapy of Cancer 2024-07-01

Pitfalls in HLA Ligandomics—How to Catch a Li(e)gand

OPENALEX - Publications

Jens Fritsche Daniel J. Kowalewski Linus Backert Frederik Gwinner Sonja Dorner and 7 more

Knowledge about the peptide repertoire presented by human leukocyte antigens (HLA) holds key to unlock target-specific cancer immunotherapies such as adoptive cell therapies or bispecific T engaging receptors. Therefore, comprehensive and accurate characterization of HLA peptidomes mass spectrometry (immunopeptidomics) across tissues disease states is essential. With growing numbers immunopeptidomics datasets scope identification strategies reaching beyond canonical proteome, likelihood for...

10.1016/j.mcpro.2021.100110 article EN cc-by-nc-nd Molecular & Cellular Proteomics 2021-01-01

Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial

OPENALEX - Publications

Martin Wermke Dejka M Araurjo Manik Chatterjee Apostolia M. Tsimberidou Tobias A.W. Holderried and 35 more

In contrast to chimeric antigen receptor T cells, cell (TCR)-engineered cells can target intracellular tumor-associated antigens crucial for treating solid tumors. However, most trials published so far show limited clinical activity. Here we report interim data from a first-in-human, multicenter, open-label, 3 + dose-escalation/de-escalation phase 1 trial studying IMA203, an autologous preferentially expressed in melanoma (PRAME)-directed TCR therapy HLA-A*02+ patients with PRAME+ recurrent...

10.1038/s41591-025-03650-6 article EN cc-by-nc-nd Nature Medicine 2025-04-09

Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer

OPENALEX - Publications